| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020277867 |
| P356 | DOI | 10.1186/1471-2407-9-199 |
| P932 | PMC publication ID | 2708190 |
| P698 | PubMed publication ID | 19549303 |
| P5875 | ResearchGate publication ID | 26313768 |
| P2093 | author name string | Anne-Marie Faussat | |
| Hamid Morjani | |||
| Ollivier Legrand | |||
| Fanny Fava | |||
| Jean-Pierre Marie | |||
| Ruoping Tang | |||
| Jean-Yves Perrot | |||
| Zora Marjanovic | |||
| Claudia Zuany-Amorim | |||
| Elise Corre | |||
| Simy Cohen | |||
| P2860 | cites work | Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells. | Q53780184 |
| Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. | Q53873000 | ||
| JC-1: a very sensitive fluorescent probe to test Pgp activity in adult acute myeloid leukemia. | Q54023674 | ||
| Class III -Tubulin Expression and Benefit from Adjuvant Cisplatin/Vinorelbine Chemotherapy in Operable Non-Small Cell Lung Cancer: Analysis of NCIC JBR.10 | Q57272633 | ||
| Antimitotic Activity of the Potent Tumor Inhibitor Maytansine | Q67429634 | ||
| Expression of normal myeloid-associated antigens by acute leukemia cells | Q69990612 | ||
| Further investigations on the expression of HLA-DR, CD33 and CD13 surface antigens in purified bone marrow and peripheral blood CD34+ haematopoietic progenitor cells | Q72088853 | ||
| Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study | Q73292530 | ||
| Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia | Q28202341 | ||
| Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer | Q28251547 | ||
| Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). | Q33319637 | ||
| Early Clinical Study of an Intermittent Schedule for Maytansine (NSC-153858): Brief Communication 2 | Q33476825 | ||
| MDR1/P-GP expression as a prognostic factor in acute leukemias. | Q33740303 | ||
| Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer | Q34203414 | ||
| Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. | Q34522032 | ||
| Controversies in treatment of AML: case-based discussion | Q36662157 | ||
| Cytoskeleton and paclitaxel sensitivity in breast cancer: the role of beta-tubulins | Q38305006 | ||
| Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines | Q38507698 | ||
| Maytansine | Q39785130 | ||
| A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. | Q40055597 | ||
| MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia | Q40352994 | ||
| Gefitinib reverses breast cancer resistance protein-mediated drug resistance | Q40515752 | ||
| Phase I study of maytansine using a 3-day schedule | Q40887319 | ||
| Initial clinical trials of maytansine, an antitumor plant alkaloid | Q40887323 | ||
| Maytansine: a phase I study of an ansa macrolide with antitumor activity | Q40887329 | ||
| Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin | Q43700140 | ||
| Prediction of response to docetaxel by quantitative analysis of class I and III beta-tubulin isotype mRNA expression in human breast cancers. | Q44545565 | ||
| Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. | Q45304360 | ||
| New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents | Q46817128 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| cytotoxicity | Q246181 | ||
| P304 | page(s) | 199 | |
| P577 | publication date | 2009-06-23 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients | |
| P478 | volume | 9 |
| Q90494509 | An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules |
| Q27022321 | Antibody Drug Conjugates: Preclinical Considerations |
| Q44746659 | Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology |
| Q37349113 | Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia |
| Q38017203 | Designing immunoconjugates for cancer therapy |
| Q34773994 | Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC. |
| Q47161864 | Encapsulation of Piper cabralanum (Piperaceae) nonpolar extract in poly(methyl methacrylate) by miniemulsion and evaluation of increase in the effectiveness of antileukemic activity in K562 cells |
| Q36614947 | Ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017): a novel scaffold that resensitizes multidrug resistant leukemia cells to chemotherapy |
| Q33690881 | Hematopoietic stem cells exhibit a specific ABC transporter gene expression profile clearly distinct from other stem cells |
| Q92462117 | In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy |
| Q47562583 | Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment. |
| Q37818256 | Investigational antibody-drug conjugates for hematological malignancies |
| Q47661007 | Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. |
| Q83967551 | Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia |
| Q45792529 | Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II. |
| Q46871150 | Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. |
| Q39182945 | Strategies and challenges for the next generation of antibody-drug conjugates |
| Q39348723 | Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment |
| Q50886676 | Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein. |
| Q35446333 | Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates |
| Q38262066 | Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates |
Search more.